Wockhardt Limited , a prominent player in the Indian pharmaceutical sector, has reported a turnaround in its financial performance for the second quarter of fiscal year 2026. The company posted a profit after tax of Rs. 82.00 crore for Q2FY26, compared to a loss of Rs. 109.00 crore in the previous quarter.

Financial Highlights

• Revenue from operations stood at Rs. 782.00 crore in Q2FY26, up from Rs. 738.00 crore in Q1FY26.
• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a significant 58% quarter-on-quarter growth, reaching Rs. 160.00 crore in Q2FY26 compared to Rs. 101.00 crore in the previous quarter.
• The company reported a profit before tax of Rs. 91.00 crore for Q2FY26, a substantial improvement from the loss of Rs. 109.00 crore in Q1FY26.

Exit from US Generic Pharmaceutical Business

In a strategic move, Wockhardt has decided to exit the US generic pharmaceutical business. The company filed for voluntary liquidation on July 11, 2025, under Chapter 7 of the US Bankruptcy Code for its US step-down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC. This decision resulted in an exceptional item charge of Rs. 97.00 crore in the financial results for the period ended September 30, 2025.

Business Performance

• The India Business reported a revenue of Rs. 172.00 crore in Q2FY26, showing a 3% growth compared to the previous year.
• UK Business revenue stood at Rs. 313.00 crore, with a 4% year-on-year growth.
• Irish Business saw significant growth, with revenue reaching Rs. 59.00 crore, a 40% increase compared to the previous year.

Novel Antibiotics Progress

Wockhardt continues to make strides in its novel antibiotics portfolio:

1. ZAYNICH®: The company submitted a New Drug Application (NDA) to the U.S. FDA in September 2025 for its novel antibacterial agent WCK 5222, ZAYNICH.

2. MIQNAF® (Nafithromycin): Approved and launched in India on May 27, 2025. The Phase 3 CABP study was published in the prestigious LANCET journal.

3. EMROK/EMROK O: Included in Clinical Infectious Disease Society's official diagnosis and treatment guidelines for 2025.

Biotech Operations

The Biotech segment showed robust growth, with overall operations for the quarter standing at Rs. 154.00 crore, recording a growth of 42% compared to Q4 FY25 and 41% versus Q1 FY26.

Intellectual Property

Wockhardt continues to strengthen its intellectual property portfolio:

• 7 patents were filed during the quarter ended September 30, 2025.
• The company was granted 5 patents during the quarter and now holds a total of 858 patents.

Wockhardt's Chairman, Dr. Habil Khorakiwala, stated, "Our focus on novel antibiotics and strategic decisions are beginning to show positive results. The exit from the US generic business allows us to concentrate on high-growth areas and innovative products."

As Wockhardt continues to navigate the challenging pharmaceutical landscape, investors and industry observers will be keenly watching its progress in novel antibiotics and the impact of its strategic decisions on future growth.

Wockhardt , a prominent pharmaceutical company, has reported a significant turnaround in its financial performance for the second quarter and made progress in its drug development efforts.

Financial Highlights

Revenue and Profitability

Wockhardt has demonstrated a remarkable improvement in profitability for Q2. The company's revenue stood at ₹782.00 crore, up by 5.96% from ₹738.00 crore in the previous quarter.

The company's focus on operational efficiency has yielded positive results. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) saw a substantial increase of 58.42%, reaching ₹160.00 crore compared to ₹101.00 crore in the previous quarter.

Turnaround in Profit Before Tax

The most striking feature of Wockhardt's Q2 results is the turnaround in profit before tax. The company reported a profit before tax of ₹91.00 crore, reversing the loss of ₹109.00 crore incurred in the previous quarter. This represents a significant improvement in the company's bottom line and reflects positively on its financial health.

Business Segment Performance

• Biotech business: Recorded 42% growth with operations at ₹154.00 crore.
• India business: Stood at ₹172.00 crore with 3% growth compared to the previous year.
• UK business: Reached ₹313.00 crore with 4% growth compared to the previous year.
• Irish business: Achieved ₹59.00 crore with 40% growth compared to the previous year.

Drug Development Milestone

Wockhardt has completed its New Drug Application (NDA) submission to the US FDA for its novel antibacterial agent WCK 5222 (ZAYNICH) for treating complicated urinary tract infections. This marks a significant achievement as it is the first-ever NDA submission to the US FDA for a drug fully discovered and developed by an Indian pharmaceutical company.

Intellectual Property

The company continues to strengthen its intellectual property portfolio:

• Filed 7 patents during the quarter
• Granted 5 patents
• Total patents held now stand at 858

Conclusion

Wockhardt's Q2 results demonstrate a robust financial performance, marked by significant improvements in profitability and operational efficiency across various business segments. The company's ability to enhance its EBITDA and achieve a substantial profit before tax indicates a positive trajectory. Additionally, the submission of the NDA for WCK 5222 represents a major milestone in Wockhardt's drug development efforts, potentially opening new avenues for growth in the future.